Do you ever use molecular assays such as Oncotype to modify your recommendations for withholding RT after lumpectomy in invasive breast cancer?
2
1 Answers
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network
This is part of the ongoing IDEA study. At present, we don't use Oncotype DX information for withholding RT for invasive breast cancer after lumpectomy.